Before Doctolib and Dataiku became familiar names, they passed through a Paris incubator with laboratories, patient advisers and no appetite for their equity. Agoranov’s next test is making more room for the companies that outgrow it.
In Trieste, a public research organisation pairs funding with access to microscopes, genomics and computing. Its bet: give difficult ideas the equipment and expertise to prove themselves.